Two stocks in Healthcare
argenx vs Novartis: profit, growth, debt and price compared
argenx is stronger on 5 of 6 figures: profit margin, sales growth, debt, analysts' view and price trend. Novartis is stronger on 1: price for its expected profit.
Save both stocks to your watchlist and revisit their latest fundamentals.
| argenxARGX.BR | NovartisNOVN.SW | |
|---|---|---|
| Net margin | Stronger: 31.7% | 17.5% |
| Revenue growth, past year | Stronger: +52.10% | +4.70% |
| Debt to equity | Stronger: 0.6% | 128.6% |
| Forward P/E | 26.9× | Stronger: 15.9× |
| Dividend yield | — | 2.78% |
| Analysts | Stronger: Buy · 23 | Hold · 22 |
| From its 200-day average | Stronger: +11.9% | +9.2% |
Share price over the past year
- argenx+9.4%
- Novartis+27.7%
24 Nov 202518 Nov 2026
argenx or Novartis: which is stronger?
- ARGX.BR
Which is more profitable?
argenx keeps more of each sale as profit: 31.7% against 17.5%.
- ARGX.BR
Which is growing its sales faster?
argenx is growing its sales faster: +52.10% over the past year, against +4.70%.
- ARGX.BR
Which has borrowed less?
argenx has borrowed less: its debt is 0.6% of what its shareholders own, against 128.6% for Novartis.
- NOVN.SW
Which costs less for the profit it is expected to make?
Novartis costs less for the profit it is expected to make: 15.9× its forward earnings, against 26.9×.
Which pays more in dividends?
Novartis pays 2.78% a year in dividends for what a share costs, where argenx pays none.
- ARGX.BR
Which do analysts rate higher?
Analysts are warmer on argenx: Buy, against Hold for Novartis.
- ARGX.BR
Which is in the stronger price trend?
argenx's price is in the stronger trend: 11.9% above its 200-day average, against 9.2% above.
What each company does
ARGX.BRargenx
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Reports results on 25 February 2027
NOVN.SWNovartis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Reports results on 3 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.